Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Torcetrapib/atorvastatin combination therapy.

Harold Bays1, James McKenney, Michael Davidson

  • 1L-MARC Research Center, 3288 Illinois Avenue, Louisville, KY 40213, USA. HBays@aol.com

Expert Review of Cardiovascular Therapy
|September 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Severe Hypertriglyceridemia Managed in a Pregnant Patient Using Nonstatin Therapies.

JACC. Case reports·2026
Same author

Negative symptoms in schizophrenia: Methodological challenges and emerging solutions for outcome measurement.

Neuroscience applied·2026
Same author

Xanomeline/trospium and suicide-related events in schizophrenia: An early pharmacovigilance analysis.

Schizophrenia research·2026
Same author

Moderate to severe negative symptoms predict low risk of symptoms worsening in schizophrenia patients in CATIE.

Schizophrenia research·2026
Same author

Modeling Negative Symptom Domain Neurobiology: Protocol for an Observational, Transdiagnostic, Translational Study.

JMIR research protocols·2026
Same author

Quality of life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: Data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST).

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
Same journal

Contemporary approach and key considerations to asymptomatic aortic stenosis treatment.

Expert review of cardiovascular therapy·2026
Same journal

Giant cell myocarditis or sarcoidosis? Time to develop clinically driven non-invasive decision algorithms in inflammatory myocardial diseases: integrating clinical features, biomarkers and multimodality imaging.

Expert review of cardiovascular therapy·2026
See all related articles

Combining atorvastatin and torcetrapib offers improved lipid profiles for reducing coronary heart disease (CHD) risk. This novel combination therapy targets both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol for enhanced cardiovascular protection.

Area of Science:

  • Cardiovascular Pharmacology
  • Lipid Metabolism
  • Drug Development

Background:

  • Elevated low-density lipoprotein cholesterol (LDL-C) significantly increases atherosclerotic coronary heart disease (CHD) risk.
  • Atorvastatin, a statin, effectively lowers LDL-C but offers limited CHD risk reduction alone.
  • Low high-density lipoprotein cholesterol (HDL-C) levels are also linked to increased CHD risk.

Purpose of the Study:

  • To review the combination agent torcetrapib/atorvastatin for complementary lipid benefits.
  • To evaluate the potential of this combination to reduce CHD risk beyond atorvastatin monotherapy.
  • To examine the chemistry, mechanism of action, pharmacokinetics, metabolism, safety, and efficacy of the combined agent.

Main Methods:

  • Review of existing literature on atorvastatin and torcetrapib.

Related Experiment Videos

  • Analysis of preclinical and clinical data for the combination therapy.
  • Examination of lipid-modifying actions and cardiovascular outcomes.

    • Main Results:

    • Torcetrapib, a cholesteryl ester transfer protein inhibitor, primarily raises HDL-C.
    • The combination of atorvastatin and torcetrapib demonstrates significant improvements in lipid profiles.
    • Complementary actions on LDL-C and HDL-C suggest enhanced efficacy for CHD risk reduction.

    Conclusions:

    • The combination of torcetrapib and atorvastatin offers synergistic lipid-modifying effects.
    • This dual-action agent holds promise for achieving greater CHD risk reduction than atorvastatin alone.
    • Further development and evaluation of this combination therapy are warranted.